

# The Hematology Research Unit



## Annual report 2023

# Introduction

The Hematology Department was established in 2003, and the Research Unit was established in 2004.

Since 2017, Head of Research has been professor Niels Abildgaard, e-mail: [niels.abildgaard@rsyd.dk](mailto:niels.abildgaard@rsyd.dk)

Daily manager in the unit is Pia Kirsten Pedersen, e-mail: [pia.k.pedersen@rsyd.dk](mailto:pia.k.pedersen@rsyd.dk)

Research secretary is Vickie Svane Kristensen, e-mail: [vickie.svane.kristensen@rsyd.dk](mailto:vickie.svane.kristensen@rsyd.dk)

Our annual report for 2021 provided a thorough description of the historical development of our Research Unit. It can be found on our [website](#).

The report for 2023 focuses on our achievements in 2023.

# Major achievements in 2023

Adjunct professor Madeleine King, Sydney, Australia, and adjunct professor Ole Weiss Bjerrum both had their adjunction to SDU and the Haematology Research Unit extended. In total, we have 3 adjunct professors and 3 professors at the Research Unit.

We treated our first patient with CAR-T cell therapy in the clinical study, CARTITUDE-5. More CAR-T cell protocols for patients with multiple myeloma and lymphomas were accepted and undergoing initiation.

Within the Centre for Cellular Immunotherapy of Hematological Cancer Odense (CITCO), which is a close collaboration with the Department of Clinical Immunology, our first academic CAR-T was established and underwent *in vivo* testing in mice. A protocol for a human phase 1 study was in process.

Our application for international accreditation according to JACIE was ongoing, and we had an inspection.

We consolidated our activities in early phase clinical trials, including activation of new “first-in-human” (FIH) studies.

There were six ongoing PhD-studies. Find a short description of the projects later in the report. Find completed theses [here](#).

# About this report

We reached our major goals for research activity and production in 2023. The following pages summarize our

- Organization
- Research Teams
- Research Centers
- User Council for Research
- Clinical trial activity
- Research production
- Research grants
- PhD projects
- List of peer-reviewed publications in 2023

# Our organization

Our human resources in 2023 counted a total of 40 employees, including TAPs and named VIPs

- 3 professors, Niels Abildgaard (Head of Research), Henrik Frederiksen (Clinical Professor), Charlotte Guldborg Nyvold (Professor in Molecular Hematology)
- Daily manager, Pia K. Pedersen
- 5 associate clinical professors, Thomas Stauffer Larsen, Thomas Lund, Claus Marcher, Duruta Weber, and Lene Granfeldt Østgaard
- Associate professor in Nursing Research, Nana Hyldig
- 3 adjunct professors, Madeleine King, Ole Weiss Bjerrum, and Tarec El-Galaly
- 5 Post docs – Jakub Krejcik, Lene Kongsgaard Nielsen, Rikke Faebo Larsen, Marcus Høy Hansen, and Simone Valentin Hansen
- 6 PhD students
- Research coordinator/fundraiser, Tine Rosenberg
- Specialist senior consultant, Sally Grant
- 4 clinical project nurses and 11 study coordinators
- Research secretary Vickie Svane Kristensen

# Plasma cell neoplasms



The research team is headed by Professor Niels Abildgaard.

Primary research areas of the team are multiple myeloma, AL amyloidosis, and Waldenstrom macroglobulinemia. The research includes clinical research, basic laboratory research, and research within the fields of health-related quality of life, patient-reported outcome (PRO), and health economics.

Diagnostics and treatment of multiple myeloma bone disease and AL amyloidosis are areas of particular interest. Home-based anti-neoplastic treatment is another area of special interest. Several clinical trials within these areas are conducted.

Niels Abildgaard heads Odense Amyloidosis Centre, AmyC OUH, appointed as Center of Clinical Excellence in 2017.

Senior researchers in the team are associate professor, consultant, PhD Thomas Lund; consultant, PhD Charlotte Toftmann Hansen; consultant, PhD Ida Bruun Kristensen; staff specialist, PhD Jakub Krejcik, and staff specialist Mette N. Christoffersen. Three PhD-studies are ongoing, and three part-time post docs are active within the team.

The team is represented in several academic study groups, including the Danish Myeloma Study Group (DMSG), the Nordic Myeloma Study Group (NMSG), the European Myeloma Network (EMN), the International Society of Amyloidosis (ISA), and the International Myeloma Working Group (IMWG).



# Benign haematology and epidemiology

The team is headed by Professor Henrik Frederiksen.

Primary research areas of the team are frequency and complications of a variety of benign hematological diseases, including hemolytic anemias, congenital red blood cell diseases, immune thrombocytopenia, and TTP. Moreover, age, comorbidity, and complications of hematological cancer as well as risk of new cancer are studied.

Randomized, controlled studies are conducted together with studies on Quality of Life. Other methods include mathematical modeling and artificial intelligence/machine learning.

Senior researcher in the team is staff specialist, PhD Dennis Lund Hansen. One PhD-study, two research assistant studies and one pre-graduate project are ongoing.

The team collaborates with national researchers and groups across Denmark within epidemiology, biostatistics, and hematology. International collaborations extend to France, Italy, Norway, Holland, UK, and USA. Through these collaborations, the department also participates in several clinical research protocols.

# Malignant lymphomas



The team is headed by Associate Professor, Chief Consultant, PhD Thomas Stauffer Larsen.

Other senior researchers are professor, Henrik Frederiksen; consultant, PhD, Jacob Haaber Christensen; lead consultant, PhD, Karen Juul-Jensen; lead consultant, PhD, Maja Bech Juul; consultant, Annika Rewes; staff specialist, PhD, Peter Brændstrup; and staff specialist Thomas Bech Mortensen.

The primary research area of the team is B-cell lymphomas, which are explored through both clinical and basic laboratory research. In addition, register-based research is conducted to uncover the prevalence and prognosis of different lymphoma subtypes. One PhD study is currently ongoing. Moreover, the team runs a large number of clinical trials, covering early phase 1/First-in-Human to post-registration, phase 4 trials. During 2023, initiation of CAR-T cell studies in lymphoma patients was ongoing.

The team is represented in the Danish Lymphoma Group (DLG) and the Nordic Lymphoma Group (NLG) and is engaged in international collaborative groups conducting clinical trials, such as the European Mantle Cell Network and International Extranodal Lymphoma Study Group (IELSG).

The team actively participates in collaborations with the Centre for Cellular Immunotherapy of Hematological Cancer Odense (CITCO) and the Academy of Geriatric Cancer Research (AgeCare) at OUH.

Adjunct professor Tarek El-Galaly is particularly involved in the research of this team.





# Myeloid disorders

The research team is headed by Associate Professor, Chief Consultant, PhD Claus W. Marcher.

Primary research areas of the team are myelodysplastic syndrome, acute leukemia, mastocytosis, and hypereosinophilic syndrome. The research includes clinical research, stem cell research, register-based research, and basic laboratory research.

Other senior researchers include Associate Professor, Chief Consultant, PhD, Duruta Weber; Associate Professor, Chief Consultant, DMSc, PhD, Lene Østgaard Granfeldt; Lead Consultant, PhD, Lene Østergaard Jepsen; Consultant Klas Raaschou-Jensen; Consultant Andreja Dimitrijevic; Consultant Mette Brabrand; Consultant Gunhild Thomsen; Staff Specialist, PhD, Dennis Lund Hansen; and Head of Department, PhD, Hanne Vestergaard.

Further, Adjunct Professor, DMSc, Ole Weiss-Bjerrum is associated with the research of the team.

The team is a major collaborator in the Mastocytosis Center OUH (MastOUH) and the Center for Eosinophilia Odense (CEOS). Moreover, the team is represented in several academic study groups including the Acute Leukemia Group (ALG), the Danish Society for Chronic Myeloproliferative Diseases (DSKMS), the Nordic CML Study Group, the Nordic MDS Group (NMDS), and the Nordic AML Group (NAMLG).

# Cancer biology and molecular hematology



Professor Charlotte Guldborg Nyvold heads the Hematology-Pathology Research Laboratory, (HPF).

At HPF, the research team conducts laboratory research within the field of hematology in close collaboration with hematologists at the Department of Hematology and hematopathologists at the Department of Pathology. The molecular heterogeneity of malignant B-cell diseases, specifically, malignant B cell lymphomas and multiple myeloma is of particular interest. The research team possess expertise in a wide range of molecular techniques, such as biobanking, flow cytometry, cell sorting, functional cell culture studies, and next generation sequencing, including exome and whole genome sequencing, transcriptome sequencing, long-read sequencing, and single cell sequencing.

Senior researchers in the team are molecular biologist and bioinformatician, PhD Marcus Høy Hansen; molecular biologist, PhD Oriane Cédile; and molecular biologist, PhD Simone Valentin Hansen. Three PhD-studies and two pre-graduate projects are ongoing, as well as the daily management of our biobank.

The team is represented in several academic study groups including the Danish Lymphoma Group, Nordic Myeloma Study Group, Nordic Lymphoma Group, and European Leukemia Network and is involved in both national and international collaborations.



# Research Group for Supportive Care

The research team is headed by associate professor, nurse, MSc, PhD Nana Hyldig.

This is a new research team established in 2022. The primary research areas are supportive care, covering the whole spectrum from diagnosis to terminally ill patients.

The team is cross-disciplinary, and both quantitative and qualitative research methods are applied. Patient and relative perspectives are in focus, and use of patient reported outcome measurements (PROM) is integrated in collaboration with our Quality of Life Research Center (QoL Research OUH).

Senior researchers in the team are professor Niels Abildgaard; professor Henrik Frederiksen; Lead Consultant, PhD Lene Østergaard Jepsen, and other researchers in the team are MD Louise Redder; nurse, MSc Anne Møller Clausen; developmental nurse Birgit Jakobsen, and User Council representatives.

The team has been closely involved in the establishment of a national cross-disciplinary research network within Hematology. This was established in 2023.

Two PhD studies are upcoming, and two pre-graduate projects are ongoing.

# Research Centers

## The Hematology Research Unit hosts:

The **Quality of Life Research Center**, QoL Research OUH, center coordinator is MSc, Tine Rosenberg, e-mail: [tine.rosenberg@rsyd.dk](mailto:tine.rosenberg@rsyd.dk) . Academic lead is MD, PhD Lene Kongsgaard Nielsen, [lene.Kongsgaard.Nielsen@rsyd.dk](mailto:lene.Kongsgaard.Nielsen@rsyd.dk).

The center of clinical excellence, **Odense Amyloidosis Center**, AmyC OUH, [www.amyloidosis.dk](http://www.amyloidosis.dk) , center director is professor Niels Abildgaard, e-mail: [niels.abildgaard@rsyd.dk](mailto:niels.abildgaard@rsyd.dk)

**The Hematology Research Unit is a partner** in the following OUH based Research Centers:

**CITCO** – Center for Cellular Immunotherapy in Hematological Cancer

**MastOUH** – Center for Mastocytosis

**AgeCare** – Academy of Geriatric Cancer Research

**CEOS** – Center for Eosinophilia Odense

**PREmedico** – Multidisciplinary OUH Center for precision medicine

# User Council for Research

To strengthen the dialogue and collaboration with patients and relatives, we established a User Council for Research at the Department of Hematology in 2017. Currently, six patients and one relative comprise the Council.


Three times a year, the Council is invited to dialogue meetings at the department, where upcoming and ongoing projects are discussed, and achieved research results are presented and discussed.

Between meetings, the user councilors are involved in writing layman paragraphs for e.g. grant applications, patient information material, among other things.

In 2023, we have expanded the collaboration and involved user representatives as project partners in some projects, and the council was also represented in employment committees.

The User Council is invited to participate in our research events and seminars at the Department of Hematology.


# 2019-2023, Clinical Trials



We have continued high activity in initiating and running clinical trials.  
In 2023, 13 new clinical trials were initiated.

# 2019-2023

## Initiated trials by study phase category




In recent years, it has been our strategy to increase the number of early phase 1-2 clinical trials, which typically involve treatment with new therapeutics.

During 2023 we have been in process to establish a physical “Phase 1 Unit”, which will allow us to formalize the running of early phase studies.

# 2019-2023


## Initiated studies by sponsor category



It is our goal to balance initiation of investigator-initiated clinical trials (IICT) and trials that are initiated and sponsored by pharmaceutical companies. As expected, there is some year-to-year variation in this.



# 2007-2023 Publications




Overall, since 2007, we have been successful in increasing the number of peer-reviewed publications as well as the number of first and/or last authorships. In 2023, we had a minor decrease in the number of publications but increase in the number of first and/or last authorships.

# Journal ranking

## Publications in Top Journal Percentiles by SJR

Entity: Hæmatologi April 2024 · Within: All subject areas (ASJC) · Year range: 2018 to 2023 · Data source: Scopus, up to 27 Mar 2024

Share of publications in Hæmatologi April 2024 that are in the top journals by SJR



211 (36.9%)

number of publications in the top 10% journals by SJR

- % publications in top 10% journals
- % publications in top 1% journals
- ▨ Incomplete year


According to OUH/SDU goals, 40% of publications should be in Scimago Journal Rank top 10%. This has nearly been achieved (36.9%).

# Journal ranking

## Publications by Journal quartile

Entity: Hæmatologi April 2024 · Within: All subject areas (ASJC) · Year range: 2018 to 2023 · Data source: Scopus, up to 27 Mar 2024

### Share of publications per Journal quartile by SJR



▨ Incomplete year

Quartiles	Publications	Publication share (%)
■ Q1 (top 25%)	427	74.7
■ Q2 (26% - 50%)	89	15.6
■ Q3 (51% - 75%)	29	5.1
■ Q4 (76% - 100%)	27	4.7
Cumulative shares	Publications	Publication share (%)


According to OUH/SDU goals, 80% of publications should be in Scimago Journal Rank top 25%. This has nearly been reached (74.7%).

# Citation Impact

## Field-Weighted Citation Impact

Entity: Hæmatologi April 2024 · Within: All subject areas (ASJC) · Year range: 2018 to 2023 · Data source: Scopus, up to 27 Mar 2024

### Yearly breakdown



▨ Incomplete year

1.73


Field-Weighted Citation Impact of  
Hæmatologi April 2024

According to OUH/SDU goals, the field-weighted citation impact should be above 1.0. This has persistently been achieved.

# Citations

## Citations per Publication

Entity: Hæmatologi April 2024 · Within: All subject areas (ASJC) · Year range: 2018 to 2023 · Data source: Scopus, up to 27 Mar 2024




17.2

average number of citations per publication in Hæmatologi April 2024

▨ Incomplete year


# Funding

**GRANTED FUNDS**  
(2016–2019)



■ External funding  
■ Internal funding

**APPLIED FOR AND GRANTED FUNDS**  
(2020-2023)



In 2023, we submitted applications for a total of DKK 56.8 millions, hereof 56.2 to external funds. We were granted DKK 8.7 millions from external funds (granted/applied = 15.5%). External funding constituted 94%.



# Ongoing PhD study

Monitoring circulating tumor DNA in aggressive large B-cell lymphoma  
– a tool for personalized medicine

**PhD student:** MD Gayaththri Vimalathas

Aggressive large B-cell lymphoma is the most frequent type of lymphoma with an annual incidence of approximately 450 cases in Denmark. The disease is deadly, but with immuno-chemotherapy, 60-65% can be cured. Unfortunately, 30-40% of the patients will relapse or are primary refractory. When treatment is completed, the patients undergo an end-of-treatment imaging scan and enroll in a monitoring program consisting of regular clinical examinations and imaging scans. It can be difficult to determine, if activity seen on imaging scans is caused by lymphoma activity or benign conditions. Further, it is not always possible to obtain tissue biopsies for diagnostic clarification. Clinicians therefore need a more sensitive and easily accessible method that allows for longitudinal monitoring to detect residual disease and thus identify patients at risk of relapse earlier. The aim of this PhD project is to evaluate the potential utility of circulating tumor DNA in aggressive large B-cell lymphoma as a novel molecular biomarker of minimal residual disease using Next Generation Sequencing in a real-life, clinically feasible set-up. The perspectives of our project are to obtain greater diagnostic accuracy, more timely therapeutic intervention in case of residual disease or relapse, and ultimately improved patient survival.

**Supervisors:** MD, PhD, Associate Professor Thomas Stauffer Larsen, Department of Hematology, OUH; Professor, Charlotte Guldborg Nyvold, Hematology-Pathology Research Laboratory, Department of Hematology, OUH; MD, Associate Professor Michael Boe Møller, Department of Pathology, OUH; Bioinformatician, PhD Marcus Høy Hansen, Hematology-Pathology Research Laboratory, Department of Hematology, OUH.

# Ongoing PhD study

Prognostication in multiple myeloma



**PhD student:** MD Louise Redder

It can be difficult to predict how things will develop, when a patient is diagnosed with multiple myeloma. Many prognostic models have tried, but the models are not tested in the general myeloma population and are therefore not used in clinical work. The purpose of this PhD project is to verify which model can provide the most accurate prognosis for patients with multiple myeloma.

Using data from the Danish Myeloma Registry and the National Patient Registry, we will validate proposed prognostic models in the Danish myeloma population. Towards the end of the project, we will examine whether quality of life can be used to determine the prognosis. Identifying the most precise prognostic model will provide the best basis for selecting patients' treatment.

**Supervisors:** Professor Niels Abildgaard, Department of Hematology, OUH; Professor Henrik Frederiksen, Department of Hematology, OUH; MD, PhD, Associate Professor Lene Kongsgaard Nielsen, Department of Hematology, OUH; Biostatistician, Associate Professor Sören Möller, OPEN, OUH.





# Ongoing PhD study

The role of mesenchymal stromal cell  
and bone marrow stromal dysfunction in multiple myeloma

**PhD student:** MD Mette Bøegh Levring

Many patients with multiple myeloma suffer from the debilitating complication of lytic bone disease, causing fractures, pain, and immobilization; all affecting patients' quality of life. Research shows that the cause of lytic bone disease is an interaction between the malignant plasma cells and the stromal cells in the bone marrow. In this 3-year PhD-project, we investigate the bone marrow stroma of patients with multiple myeloma. We will focus on the bone forming osteoblasts and their precursor cells, mesenchymal stromal cells. We will examine the cells with both functional cell cultures and genetic transcription to characterize the cells in great detail. We will compare the characteristics of stromal cells from different stages of multiple myeloma and from healthy donors. Our mission is to understand how stromal cells are involved in the development of lytic bone disease. A better understanding of this will facilitate development of new treatment for bone disease, improving quality of life for many patients with multiple myeloma .

**Supervisors:** Professor Niels Abildgaard, Department of Hematology, OUH; Professor Charlotte Guldborg Nyvold, Hematology-Pathology Research Laboratory, Department of Hematology, OUH; Professor Moustapha Kassem, Laboratory of Molecular Endocrinology, Department of Endocrinology, OUH; MD, PhD Ida Bruun Kristensen, Department of Hematology, OUH.

# Ongoing PhD study

Treatment and Monitoring of the Bone Disease in Multiple Myeloma Patients



**PhD student:** MD Michael Tveden Gundesen

Bone disease in multiple myeloma (MM) leads to severe pain and suffering. Though great improvements have been obtained in the treatment of MM, healing the bone disease remains a clinical challenge. This project aims to evaluate the bone-healing potential of ixazomib and to determine the best method for monitoring the bone disease by evaluating the effect of different imaging modalities.

The bone-healing potential of ixazomib is tested in an explorative study of 30 patients with MM associated bone disease receiving ixazomib. Patients are followed for 2 years of treatment and evaluated by NaF-CT scans.

In another study, we follow 267 patients receiving treatment with zometa for two to four years. Zometa is a well-proven protective agent for bone disease in MM, but the treatment is not without side effects, and the optimal treatment period is unknown. The hope is that we will be able to determine the optimal treatment period to secure an optimal treatment effect with fewest possible side effects. This study is conducted in collaboration with centers of the Nordic Myeloma Study Group.

**Supervisors:** MD, PhD Thomas Lund, Department of Hematology, OUH; Professor Niels Abildgaard, Department of Hemaology, OUH; Clinical director of Oncoradiology Jon Thor Asmussen, Department of Radiology, OUH; MD Anne Lerberg Nielsen, Department of Nuclear Medicine, OUH.



# Ongoing PhD study

On adverse outcomes in immune thrombocytopenia  
– a population-based cohort study

**PhD student:** MD Nikolaj Mannering

Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by a low number of circulating platelets in the bloodstream. Patients suffer from bleedings, treatment toxicity, reduced quality of life, and shortened life expectancy. It is believed that disease complications and side effects from treatment contribute equally to complications and excess mortality. However, these observations are based on a very small number of patients and frequencies. Impact of complications from disease and treatment are not well understood.

Using data from Danish health registries, our study therefore aims at providing up-to-date knowledge on possible and yet unexplored complications and late effects to ITP. We have constructed a large population-based cohort comprising >5,000 patients with ITP and >200,000 age-sex matched comparisons from the Danish population. The patients were diagnosed during the period 1980-2016 and have complete follow-up.

During this period, the treatment options for ITP have changed radically. We will use our data to provide updated mortality and adverse health outcome effects, focusing particularly on temporal variation. Our dataset is unprecedented in this field of research.

We aim at conveying results to clinicians in order to optimize treatment, follow-up and to improve outlook for patients with ITP.

**Supervisors:** Professor Henrik Frederiksen, Department of Hematology, OUH; MD, PhD Dennis Lund Hansen, Department of Hematology, OUH; Professor Anton Pottegård, Department of Public Health, University of Southern Denmark.

# Ongoing PhD study

Drug resistance in patients with chronic lymphocytic leukemia



**PhD student:** MSc Sólja Remisdóttir Veyhe

Chronic lymphocytic leukemia is the most common type of leukemia in adults with about 450 new cases in Denmark annually. Although promising results have been obtained with the targeted treatments, ibrutinib and venetoclax, some patients still experience poor treatment response. The aim of the project is to provide novel and valuable information on the molecular pathways and kinetics involved in resistance to these drugs. The hope is that this will enable us to predict who will benefit from the treatment, before treatment start. Further, it might enable early detection of the development of resistance during treatment.

Thus, the project has the potential to influence the clinical course of each individual patient, both before and during treatment.

**Supervisors:** Professor Charlotte Guldborg Nyvold, Hematology-Pathology Research Laboratory, Department of Hematology, OUH; Professor Henrik Frederiksen, Department of Hematology, OUH; MD, PhD Karen Juul-Jensen, Department of Hematology, OUH; Professor Karen Dybkær, Department of Clinical Medicine, Aalborg University Hospital.

# Peer-reviewed publications in 2023

## **Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma**

**Abildgaard, N.**, Freilich, J., Anttila, P., Bent-Ennakhil, N., Ma, Y., Lassenius, M., Ørstavik, S., Toppila, I., Waage, A., Turesson, I. & Hansson, M., 2023, I: *Clinical Epidemiology*. 15, s. 987-999

## **Translation and Cross-Cultural Validation of the Danish Version of the Family Health Scale–Long Form: A Psychometric Study**

Alawi, S., Dieperink, K. B., Agerskov, H., Marcussen, J., Möller, S., Voltelen, B. & **Hyldig, N.**, okt. 2023, I: *Seminars in Oncology Nursing*. 39, 5, 151480.

## **Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas**

AL-Mashhadi, A. L., Jakobsen, L. H., Brown, P., Gang, A. O., Thorsteinsson, A. L., Rasoul, K., Haissman, J. M., Tøstesen, M. B., Christoffersen, M. N., Jelacic, J., Jørgensen, J. B., Thomsen, T., Dessau-Arp, A., Andersen, A. P. H., Frederiksen, M., Pedersen, P. T., Clausen, M. R., Jørgensen, J. M., Poulsen, C. B., **El-Galaly, T. C. & Larsen, T. S.**, 27. nov. 2023, (E-pub ahead of print) I: *British Journal of Haematology*.

## **Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study**

Baech, J., Husby, S., Trab, T., Kragholm, K., Brown, P., Gørløv, J. S., Jørgensen, J. M., Gudbrandsdottir, S., Severinsen, M. T., Grønæk, K., **Larsen, T. S.**, Wåsterlid, T., Eloranta, S., Smeland, K. B., Jakobsen, L. H. & **El-Galaly, T. C.**, 28. dec. 2023, (E-pub ahead of print) I: *British Journal of Haematology*.

## **Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation**

Bertelsen, L. D., Børty Nielsen, L., Christensen, H. S., Bøgsted, M., Gregersen, H., Pedersen, R. S., Klostergaard, A., Schnack, B. I., Pedersen, P. T., **Abildgaard, N.**, Hermansen, E., Vangsted, A. J. & Severinsen, M. T., mar. 2023, I: *European journal of haematology*. 110, 3, s. 289-295

## **Telomersygdomme**

Byrjalsen, A., Bygum, A., Lautrup, C. K., Frederiksen, A. L., Fialla, A., **Kræsten Raaschou Jensen**, K., Bendstrup, E., Masmás, T. N., Klarskov, M. & Jelsig, A. M., jan. 2023, I: Ugeskrift for Læger. 185, 1, V03220220.

## **Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing**

**Cédile, O., Hansen, M. H., Dahlmann, S. K., Kristensen, T. K., Abildgaard, N. & Nyvold, C. G.**, 1. mar. 2023, I: Experimental Hematology. 119-120, s. 14-20

## **Monocytosis in primary care and risk of haematological malignancies**

Christensen, M. E., Siersma, V., Kriegbaum, M., Lind, B. S., Samuelsson, J., **Ostgard, L. S. G.**, Gronbaek, K. & Andersen, C. L., apr. 2023, I: European journal of haematology. 110, 4, s. 362-370

## **Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization**

Clavero, E., Sanchez-Maldonado, J. M., Macaуда, A., Ter Horst, R., Sampaio-Marques, B., Jurczynszyn, A., Clay-Gilmour, A., Stein, A., Hildebrandt, M. A. T., Weinhold, N., Buda, G., García-Sanz, R., Tomczak, W., Vogel, U., Jerez, A., Zawirska, D., Wątek, M., Hofmann, J. N., Landi, S., Spinelli, J. J., Butrym, A., Kumar, A., Martínez-López, J., Galimberti, S., Sarasquete, M. E., Subocz, E., Iskierka-Jażdżewska, E., Giles, G. G., Rybicka-Ramos, M., Kruszewski, M., **Abildgaard, N.**, Verdejo, F. G., Sánchez Rovira, P., da Silva Filho, M. I., Kadar, K., Razny, M., Cozen, W., Pelosini, M., Jurado, M., Bhatti, P., Dudzinski, M., Druzd-Sitek, A., Orciuolo, E., Li, Y., Norman, A. D., Zaucha, J. M., Reis, R. M., Markiewicz, M., Rodríguez Sevilla, J. J., Andersen, V., Jamroziak, K., Hemminki, K., Berndt, S. I., Rajkumar, V., Mazur, G., Kumar, S. K., Ludovico, P., Nagler, A., Chanock, S. J., Dumontet, C., Machiela, M. J., Varkonyi, J., Camp, N. J., Ziv, E., Vangsted, A. J., Brown, E. E., Campa, D., Vachon, C. M., Netea, M. G., Canzian, F., Försti, A. & Sainz, J., 9. maj 2023, I: International Journal of Molecular Sciences . 24, 10, 20 s., 8500.

## **Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study**

Diaz-delCastillo, M., **Gundesén, M. T.**, Andersen, C. W., Nielsen, A. L., Møller, H. E. H., Vinholt, P. J., Asmussen, J. T., Kristensen, I. B., **Nyvold, C. G., Abildgaard, N.**, Levin Andersen, T. & **Lund, T.**, maj 2023, I: Journal of Bone and Mineral Research. 38, 5, s. 639-649

## **BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer**

Ehmsen, S., Pedersen, R. M., Bang, L. L., Asmussen, A., Kragh, A., Holm, D. K., Sydenham, T. V., Jensen, T. G., Jeppesen, S. S., **Frederiksen, H.**, Andersen, T. E. & Ditzel, H. J., 10. apr. 2023, I: Cancer Cell. 41, 4, s. 649-650

### **First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.**

Eichhorst, B., Niemann, C. U., Kater, A. P., Furstenau, M., Von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindstrom, V., Da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schottker, B., Nosslinger, T., Janssens, A., Christiansen, I., Baumann, M., **Frederiksen, H.**, Van Der Klift, M., Jager, U., Leys, M. B. L., Hoogendoorn, M., Loffi, K., Hebart, H., Gaska, T., Koene, H., Enggaard, L., Goede, J., Regelink, J. C., Widmer, A., Simon, F., De Silva, N., Fink, A. M., Bahlo, J., Fischer, K., Wendtner, C. M., Kreuzer, K. A., Ritgen, M., Bruggemann, M., Tausch, E., Levin, M. D., Van Oers, M., Geisler, C., Stilgenbauer, S. & Hallek, M., 11. maj 2023, I: New England Journal of Medicine. 388, 19, s. 1739-1754

### **Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population-based matched cohort study**

Entrop, J. P., Weibull, C. E., Smedby, K. E., Jakobsen, L. H., Øvlisen, A. K., Molin, D., Glimelius, I., Marklund, A., Holte, H., Fosså, A., Smeland, K. B., **EI-Galaly, T. C.** & Eloranta, S., 15. aug. 2023, I: International Journal of Cancer. 153, 4, s. 723-731

### **Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study**

Entrop, J. P., Weibull, C. E., Smedby, K. E., Jakobsen, L. H., Øvlisen, A. K., Glimelius, I., Marklund, A., **Larsen, T. S.**, Holte, H., Fosså, A., Smeland, K. B., **EI-Galaly, T. C.** & Eloranta, S., aug. 2023, I: British Journal of Haematology. 202, 4, s. 785-795

### **Clinical presentation and outcome of sinonasal extrasosseous plasmacytoma in Denmark: A nationwide cohort from 1980 to 2017**

Eriksen, P. R. G., Khakbaz, E., Clasen-Linde, E., Brown, P. D. N., Haunstrup, L., **Christoffersen, M.**, Asdahl, P., Thomsen, T. M., Gerner-Rasmussen, J., Heegaard, S. & von Buchwald, C., okt. 2023, I: Annals of Otolaryngology, Rhinology and Laryngology. 132, 10, s. 1186-1193

### **Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial**

Freeman, S. D., Thomas, A., Thomas, I., Hills, R. K., Vyas, P., Gilkes, A., Metzner, M., Jakobsen, N. A., Kennedy, A., Moore, R., Almuina, N. M., Burns, S., King, S., Andrew, G., Gallagher, K. M. E., Sellar, R. S., Cahalin, P., **Weber, D.**, Dennis, M., Mehta, P., Knapper, S. & Russell, N. H., 16. nov. 2023, I: Blood. 142, 20, s. 1697-1707

**Detection of infections by computerized capture of peaks in longitudinally measured C-reactive protein levels**

Garvik, O. S., Póvoa, P., Vinholt, P. J., Nielsen, S. L., Jensen, T. G., **Frederiksen, H.**, Chen, M., Dessau, R. B., Coia, J. E., Møller, J. K. & Gradel, K. O., 14. nov. 2023, I: Biomarkers in Medicine. 17, 15, s. 635-642

**Elevated Hemolysis Index is associated with higher risk of cardiovascular diseases**

Gils, C., **Hansen, D. L.**, Nybo, M. & **Frederiksen, H.**, 26. jul. 2023, I: Clinical Chemistry and Laboratory Medicine. 61, 8, s. 1497-1505

**Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population-based cohort study**

Gjærde, L. K., Jakobsen, L. H., Juhl-Christensen, C., Olesen, G., Petruskevicius, I., Severinsen, M. T., **Marcher, C. W.**, Theilgaard-Mönch, K., Andersen, N. S., Friis, L. S., Kornblit, B., Petersen, S. L., Schjødt, I. & Sengeløv, H., feb. 2023, I: British Journal of Haematology. 200, 4, s. e40-e43

**Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13**

Groen, K., Schjesvold, F. H., Van Der Holt, B., Levin, M. D., Seefat, M. R., Hansson, M., Leys, M. B. L., Regelink, J. C., Waage, A., Szatkowski, D., Axelsson, P., Hieu Do, T., Svirskaitė, A., Van Der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C. H., Mellqvist, U. H., Van De Donk, N. W. C. J., Sonneveld, P., Klostergaard, A., Vangsted, A. J., **Abildgaard, N.** & Zweegman, S., 30. sep. 2023, I: HemaSphere. 7, 9, 4 s., E940.

**Toward Cytogenomics: Technical Assessment of Long-Read Nanopore Whole-Genome Sequencing for Detecting Large Chromosomal Alterations in Mantle Cell Lymphoma**

**Hansen, M. H.**, **Cédile, O.**, Kjeldsen, M. L. G., Thomassen, M., Preiss, B., von Neuhoff, N., **Abildgaard, N.** & **Nyvold, C. G.**, nov. 2023, I: Journal of Molecular Diagnostics. 25, 11, s. 796-805

**Primary autoimmune haemolytic anaemia is associated with increased risk of ischaemic stroke: A binational cohort study from Denmark and France**

**Hansen, D. L.**, Maquet, J., Lafaurie, M., Möller, S., Berentsen, S., **Frederiksen, H.**, Moulis, G. & Gaist, D., 14. dec. 2023, (E-pub ahead of print) I: British Journal of Haematology.

**Lenalidomide Maintenance in Multiple Myeloma: A Retrospective, Nationwide, Real-World Study**

Harsløf, M., **Chanchiri, I.**, Silkjaer, T., Frølund, U. C., Todorescu, E., Grønbaek, K., Nielsen, K. B., Trøllund Pedersen, P., Iversen, K. F., Thorsteinsdottir, S., Vangsted, A. J. & Szabo, A. G., aug. 2023, I: HemaSphere. 7, S3



**Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study**

Hess, G., Dreyling, M., Oberic, L., Gine, E., Zinzani, P. L., Linton, K., **Vilmar, A.**, Jerkeman, M., Chen, J. M. H., Ohler, A., Stilgenbauer, S., Thieblemont, C., Lambert, J., Zilioli, V. R., Sancho, J.-M., Jiménez-Ubieto, A., Fischer, L., Eyre, T. A., Keeping, S., Park, J. E., Wu, J. J., Siddiqi, R., Reitan, J., Wade, S. & Salles, G., aug. 2023, I: British Journal of Haematology. 202, 4, s. 749-759

**Cell-free DNA for detection of clonal B cells in diffuse large B cell lymphoma by sequencing**

Højlund, E. L., **Cédile, O.**, **Larsen, T. S.**, **Vimalathas, G.**, Møller, M. B., **Hansen, M. H.** & **Nyvold, C. G.**, okt. 2023, I: International Journal of Laboratory Hematology. 45, 5, s. 735-742

**Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era**

**Jellicic, J.**, **Hansen, D. L.**, Carlsen, S. S., Thorsgaard, M., Hersby, D. S., Kannik, K., Munksgaard, A. S. E., **Larsen, T. S.** & **Juul-Jensen, K.**, jul. 2023, I: Annals of Hematology. 102, s. 1897-1905

**Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models**

**Jellicic, J.**, **Juul-Jensen, K.**, Bukumiric, Z., Roost Clausen, M., Ludvigsen Al-Mashhadi, A., Pedersen, R. S., Poulsen, C. B., Brown, P., **El-Galaly, T. C.** & **Stauffer Larsen, T.**, 13. okt. 2023, I: Blood Cancer Journal. 13, 12 s., 157.

**Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease**

Johansen, M., **Levring, M. B.**, Stokbro, K., Diaz-delCastillo, M., Khan, A. A., Wickstroem, L. A., **Gundesen, M. T.**, **Kristensen, I. B.**, **Nyvold, C. G.**, Andersen, M. Ø., Andersen, T. L., **Abildgaard, N.** & **Lund, T.**, 25. nov. 2023, I: Cancers. 15, 23, 18 s., 5585.

**The creation of a solo-mother family—a qualitative study**

Konge Nielsen, M., Funderskov, K. F., **Danbjørg, D. B.**, Juel Rothmann, M. & Werner, A., apr. 2023, I: Human Fertility. 26, 2, s. 373-384

**Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy**

Kristensen, D. T., Brøndum, R. F., Ørskov, A. D., **Marcher, C. W.**, Schöllkopf, C., Sørensen, A. L. T., Severinsen, M. T., Bøgsted, M. & Roug, A. S., okt. 2023, I: European journal of haematology. 111, 4, s. 573-582

**10-year nationwide trends in incidence, treatment patterns, and mortality of patients with myelodysplastic syndromes in Denmark**

Lauritsen, T. B., Nørgaard, J. M., Dalton, S. O., Grønbæk, K., **El-Galaly, T. C. & Østgård, L. S. G.**, maj 2023, I: Leukemia Research. 128, 10 s., 107056.

**Time trends in incidence and prevalence of immune thrombocytopenia: A nationwide cohort analysis**

**Lawrie, D. A., Mannering, N., Hansen, D. L. & Frederiksen, H.**, aug. 2023, I: British Journal of Haematology. 202, 3, s. 690-692

**Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group**

Ludvigsen Al-Mashhadi, A., Cederleuf, H., Kuhr Jensen, R., Holm Nielsen, T., Bjerregård Pedersen, M., **Bech Mortensen, T.**, Relander, T., Jerkeman, M., Ortvad Gang, A., Kristensen, A. L., Roost Clausen, M., de Nully Brown, P., Tang Severinsen, M., Jakobsen, L. H., Ellin, F. & **El-Galaly, T. C.**, mar. 2023, I: American Journal of Hematology. 98, 3, s. 388-397

**Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study**

Lund, L. C., Rahbek, M. T., Brown, P., Obel, N., Hallas, J. & **Frederiksen, H.**, dec. 2023, I: European journal of haematology. 111, 6, s. 946-950

**Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study**

Maksten, E. F., Jakobsen, L. H., Kragholm, K. H., Baech, J., Andersen, M. P., Madsen, J., Jørgensen, J. M., Clausen, M. R., Pedersen, R. S., Dessau-Arp, A., **Larsen, T. S.**, Poulsen, C. B., Gang, A. O., Brown, P., Fonager, K., **El-Galaly, T. C.** & Severinsen, M. T., 14. mar. 2023, I: Clinical Epidemiology. 15, s. 337-348

**Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population-based study**

**Mannering, N., Hansen, D. L.**, Pottegård, A. & **Frederiksen, H.**, feb. 2023, I: Transfusion. 63, 2, s. 415-426

**Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms**

Massarenti, L., Knudsen, T. A., Enevold, C., Skov, V., Kjaer, L., Larsen, M. K., **Larsen, T. S.**, **Hansen, D. L.**, Hasselbalch, H. C. & Nielsen, C. H., jul. 2023, I: British Journal of Haematology. 202, 2, s. 318-327

**Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden**

Moore, K. L. F., Turesson, I., Genell, A., Klausen, T. W., Knut-Bojanowska, D., **Redder, L.**, Sverrisdottir, I., Thorsen, J., Vangsted, A. J. & Blimark, C. H., 1. jun. 2023, I: Haematologica. 108, 6, s. 1640-1651

**Frequency and Functional Characterization of RUNX1 Germline Variants in Myeloid Neoplasms**

Nitschke, N. J., Almosailleakh, M., Niu, Y., Hansen, J. W., **Raaschou-Jensen, K.**, Jespersen, J. S., Severinsen, M. T., Roug, A. S., Frödin, M., Weischenfeldt, J. L., Andersen, M. K. & Grønbæk, K., 2. jul. 2023, I: Human Mutation. 2023, 11 s., 4738660.

**Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation**

Nørgaard, J. N., **Abildgaard, N.**, Lysén, A., Tsykunova, G., Vangsted, A. J., João, C., Remen, N., **Nielsen, L. K.**, Osnes, L., Stokke, C., Connelly, J. P., Revheim, M. E. R. & Schjesvold, F., okt. 2023, I: Leukemia. 37, 10, s. 2107-2114

**The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study**

Pedersen, M. A., Gormsen, L. C., Jakobsen, L. H., Eyre, T. A., Severinsen, M. T., Baech, J., Dann, E. J., Knapp, A., Sahin, D., Vestergaard, P., **El-Galaly, T. C.** & Jensen, P., 13. nov. 2023, (E-pub ahead of print) I: British Journal of Haematology.

**Sex differences in lymphoma incidence and mortality by subtype: A population-based study**

Radkiewicz, C., Bruchfeld, J. B., Weibull, C. E., Jeppesen, M. L., **Frederiksen, H.**, Lambe, M., Jakobsen, L., **El-Galaly, T. C.**, Smedby, K. E. & Wästerlid, T., jan. 2023, I: American Journal of Hematology. 98, 1, s. 23-30

**The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment**

Rich, C., Wilson, K., Olsen, J., Pedersen, M. & **Frederiksen, H.**, 27. nov. 2023, (E-pub ahead of print) I: European journal of haematology.

**Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia**

Rotbain, E. C., Allmer, C., Rostgaard, K., Andersen, M. A., Vainer, N., da Cunha-Bang, C., Parikh, S. A., Rabe, K. G., Hjalgrim, H., **Frederiksen, H.**, Slager, S. L. & Niemann, C. U., aug. 2023, I: American Journal of Hematology. 98, 8, s. 1236-1245

**Protective Buffering: Nurses Facilitating Communication Between Adults With Cancer and Their Adult Family Caregivers Who Overprotect One Another—An Integrative Review**

Rothausen, C. S., **Clausen, A. M.**, Voltelen, B. & Dieperink, K. B., nov. 2023, I: Journal of Family Nursing. 29, 4, s. 417-436

**Unsupervised item response theory models for assessing sample heterogeneity in patient-reported outcomes measures**

Sajobi, T. T., Sanusi, R. A., Mayo, N. E., Sawatzky, R., **Kongsgaard Nielsen, L.**, Sebille, V., Liu, J., Bohm, E., Awosoga, O., Norris, C. M., Wilton, S. B., James, M. T. & Lix, L. M., 21. dec. 2023, (E-pub ahead of print) I: Quality of Life Research.

**Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study**

Sonsby, L., Dueholm, J. R., **Danbjørg, D. B.**, **Abildgaard, N.** & **Kongsgaard Nielsen, L.**, maj 2023, I: Oncology Nursing Forum. 50, 5, s. 635-645

**Early Mortality in Paroxysmal Nocturnal Hemoglobinuria**

Sørensen, A. L., **Lund Hansen, D.** & **Frederiksen, H.**, okt. 2023, I: Cureus. 15, 10, e47225.

**Amyloidose er en sygdom med mange ansigter**

**Spanggaard, M. B. L.**, **Hansen, C. T.**, Maiborg, M., Rojek, A. M., Vestergaard, S., Beck, H. C., Møller, H. E. H. & **Abildgaard, N.**, 17. apr. 2023, I: Ugeskrift for Læger. 185, 8, s. 770-774 V08220479.

**Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study**

Svingel, L. S., Christensen, S. F., Kjærsgaard, A., Stenling, A., Paulsson, B., Andersen, C. L., Christiansen, C. F., Stentoft, J., Starklint, J., Severinsen, M. T., Borg Clausen, M., Hagemann Hilsøe, M., Hasselbalch, H. C., **Frederiksen, H.**, Bak, M. & Mikkelsen, E. M., 2023, I: Acta Oncologica. 62, 10, s. 1286-1294

### **The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies**

Szabo, A. G., Thorsen, J., Iversen, K. F., **Levring, M. B.**, Helleberg, C., Hermansen, E., Bønløkke, S. T., Nielsen, K., Teodorescu, E. M., Kurt, E., Strandholdt, C. N. & Vangsted, A. J., nov. 2023, I: eJHaem. 4, 4, s. 1006-1012

### **The multidisciplinary approach to eosinophilia**

Thomsen, G. N., Christoffersen, M. N., Lindegaard, H. M., Davidsen, J. R., Hartmeyer, G. N., Assing, K., Mortz, C. G., Martin-Iguacel, R., Møller, M. B., Kjeldsen, A. D., Havelund, T., El Fassi, D., Broesby-Olsen, S., Maiborg, M., Johansson, S. L., Andersen, C. L., **Vestergaard, H. & Bjerrum, O. W.**, 18. maj 2023, I: Frontiers in Oncology. 13, 24 s., 1193730.

### **Clinical challenges in the treatment of a patient with decompensated heart failure and glucose-6-phosphate dehydrogenase deficiency (G6PDd)**

Tojaga, N., Egholm, G. & **Lund Hansen, D.**, 31. okt. 2023, I: BMJ Case Reports. 16, 10, e255722.

### **Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study**

Trab, T., Baech, J., Jakobsen, L. H., Husby, S., Severinsen, M. T., Eloranta, S., Gørløv, J. S., Jørgensen, J. M., Gudbrandsdottir, S., **Larsen, T. S.**, Brown, P., Grønbæk, K., Smedby, K. E. & **El-Galaly, T. C.**, okt. 2023, I: The Lancet Haematology. 10, 10, s. e838-e848

### **Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study**

Tuyet Kristensen, D., Kisbye Øvlisen, A., Hjort Kyneb Jakobsen, L., Tang Severinsen, M., Hannig, L. H., Starklint, J., Hagemann Hilsøe, M., Pommer Vallentin, A., **Brabrand, M.**, Hasselbalch, H. C., **El-Galaly, T. C.** & Stidsholt Roug, A., 25. jul. 2023, I: Blood Advances. 7, 14, s. 3450-3457

### **Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia**

Vainer, N., Aarup, K., Andersen, M. A., Wind-Hansen, L., Nielsen, T., **Frederiksen, H.**, Enggaard, L., Poulsen, C. B., Niemann, C. U. & Rotbain, E. C., jun. 2023, I: British Journal of Haematology. 201, 5, s. 874-886

**Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study**

van de Donk, N. W. C. J., Minnema, M. C., van der Holt, B., Schjesvold, F., Wu, K. L., Broijl, A., Roeloffzen, W. W. H., Gadsisseur, A., Pietrantonio, G., Pour, L., van der Velden, V. H. J., **Lund, T.**, Offidani, M., Grasso, M., Giaccone, L., Razawy, W., Tacchetti, P., Mancuso, K., Silkjaer, T., Caers, J., Zweegman, S., Hájek, R., Benjamin, R., Vangsted, A. J., Boccadoro, M., Gay, F., Sonneveld, P. & Musto, P., okt. 2023, I: The Lancet Oncology. 24, 10, s. 1119-1133

**Increased mortality in patients with hematologic malignancies treated with proton pump inhibitors: a nationwide cohort study**

Vilmar, A., Dehlendorff, C., Friis, S., Jäättelä, M., Tvingsholm, S. & **Frederiksen, H.**, 2023, I: Leukemia and Lymphoma. 64, 8, s. 1451-1457

**The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL**

Visentin, A., Chatzikonstantinou, T., Scarfò, L., Kapetanakis, A., Demosthenous, C., Karakatsoulis, G., Minga, E., Chamou, D., Allsup, D., Cabrero, A. A., Andres, M., Antic, D., Baile, M., Baliakas, P., Besikli-Dimou, S., Bron, D., Chatzileontiadou, S., Cordoba, R., Correa, J-G., Cuéllar-García, C., De Paoli, L., De Paolis, M. R., Delgado, J., Dimou, M., Donaldson, D., Catherwood, M., Doubek, M., Efstathopoulou, M., Eichhorst, B., Elashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., **Frederiksen, H.**, Fürstenau, M., García-Marco, J. A., García-Serra, R., Collado, R., Gentile, M., Gimeno, E., Glenthøj, A., da Silva, M. G., Hakobyan, Y. K., Herishanu, Y., Hernández-Rivas, J. Á., Herold, T., Innocenti, I. & Itchaki, G., dec. 2023, I: American Journal of Hematology. 98, 12, s. 1856-1868

**Impact of U2AF1 mutations on circular RNA expression in myelodysplastic neoplasms**

Wedge, E., Ahmadov, U., Hansen, T. B., Gao, Z., Tulstrup, M., Côme, C., Nonavinkere Srivatsan, S., Ahmed, T., Jespersen, J. S., Schlotmann, B. C., Schöllkopf, C., **Raaschou-Jensen, K.**, Ødum, N., Kjems, J., Bak, R. O., Walter, M. J., Grønbæk, K. & Kristensen, L. S., maj 2023, I: Leukemia. 37, 5, s. 1113-1125

**Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study**

Zinzani, P. L., Trněný, M., Ribrag, V., Zilioli, V. R., Walewski, J., **Christensen, J. H.**, Delwail, V., Rodriguez, G., Venugopal, P., Coleman, M., Dartigeas, C., Patti, C., Pane, F., Jurczak, W., Taszner, M., Paneesha, S., Zheng, F., DeMarini, D. J., Jiang, W., Gilmartin, A. & Mehta, A., aug. 2023, I: eClinicalMedicine. 62, 12 s., 102131.